A multicenter, randomized, open-label, parallel-group, phase 3 trial of subcutaneous azacitidine plus best supportive care versus conventional care regimens plus best supportive care for the treatment of myelodysplastic syndromes

Trial Profile

A multicenter, randomized, open-label, parallel-group, phase 3 trial of subcutaneous azacitidine plus best supportive care versus conventional care regimens plus best supportive care for the treatment of myelodysplastic syndromes

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine; Daunorubicin; Idarubicin; Mitoxantrone
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 24 May 2017 Results developing cost-effectiveness survival analysis model using patient data of this study presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 08 Dec 2015 Results (safety analysis of AZA-AML-001 (n = 236) and AZA-001 (n = 175) studies) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 20 Jun 2011 New source identified and integrated (European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top